Atelerix Life Sciences

  • info@atelerixlifesciences.com
Facebook Twitter Linkedin

[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

DISCOVERING OUR LEAD COMPOUND

[/vc_column_text][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]Based on overall chemical stability, efficacy, negligible cardiovascular effects, and onset profiles, ATLX-0199 (D-Cystine diME) was selected as the lead compound for clinical development, with back-up compounds available.  ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.[/vc_column_text][vc_single_image image=”263″ img_size=”full” alignment=”center”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_separator type=”normal”][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

PLATFORM/PIPELINE

Lead compound ATLX-0199 ready for clinical development, with platform molecules available

[/vc_column_text][vc_single_image image=”264″ img_size=”full” alignment=”center” qode_css_animation=””][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_separator type=”normal”][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]

HOW IT WORKS

[/vc_column_text][vc_column_text]

ATLX-0199, an active thiol-based compound from our platform of novel drugs, reverses opioid-induced side effects such as OIRD while preserving pain relief:

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]

  • ATLX-0199 targets molecular pathways, modulating signals downstream from activated opioid receptors
  • Concept validated by extensive NIH-supported research/data
  • Atelerix is developing ATLX-0199 and other compounds in its pipeline to treat the range of opioid-induced side effects; first focus is OIRD in the hospital surgical setting

[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_single_image image=”259″ img_size=”full” alignment=”center”][/vc_column_inner][/vc_row_inner][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_column_text]

AVAILABLE DATA

[/vc_column_text][vc_column_text]

In-vitro & in-vivo data show compelling pre-clinical proof of concept

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/3″ css=”.vc_custom_1617817566583{border-radius: 1px !important;}”][/vc_column_inner][vc_column_inner width=”1/3″ css=”.vc_custom_1617817653067{border-radius: 1px !important;}”][vc_column_text]

ATLX-0199 (D-Cystine diME)

[/vc_column_text][vc_separator type=”normal”][vc_column_text]

  • ATLX-0199 increases minute ventilation and overcomes opioid-induced respiratory depression.
  • ATLX-0199 (D-Cystine diME) reverses the respiratory depression and V/Q mismatch after 10 mg/kg IV morphine in conscious rats.
  • ATLX-0199 (D-Cystine diME) does not negatively impact the analgesic actions of morphine in freely-moving rats.

[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][/vc_column_inner][/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_empty_space][vc_column_text]

Additional data on opioid withdrawal response, tolerance, motility, modulation of addiction and co-administration with naloxone is available under CDA

[/vc_column_text][vc_empty_space][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_column_text]

PRE-CLINICAL PROOF OF CONCEPT

[/vc_column_text][vc_column_text]

ATLX-0199 increases minute ventilation and overcomes opioid-induced respiratory depression

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/3″][vc_single_image image=”208″ img_size=”full” qode_css_animation=””][/vc_column_inner][vc_column_inner width=”1/3″][vc_single_image image=”209″ img_size=”full” qode_css_animation=””][/vc_column_inner][vc_column_inner width=”1/4″][vc_column_text]Minute ventilation (VE) is the total volume of gas entering (or leaving) the lung per/min

It is equal to the tidal volume (TV) multiplied by the respiratory frequency rate (f).

VE = TV x f[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_column_text]

No toxicity observed to date at maximal effective doses

[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_column_text]

PRE-CLINICAL PROOF OF CONCEPT

[/vc_column_text][vc_column_text]

ATLX-0199 reverses the respiratory depression and V/Q mismatch after 10 mg/kg IV morphine in conscious rats

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/4″][vc_column_text]Studied blood gas parameters include:

Blood pH

Increases in CO2

Hemoglobin saturation

Oxygen imbalance between lungs and arteries[/vc_column_text][/vc_column_inner][vc_column_inner width=”3/4″][vc_single_image image=”210″ img_size=”full” qode_css_animation=””][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_separator type=”normal”][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

PRE-CLINICAL PROOF OF CONCEPT

[/vc_column_text][vc_column_text]

ATLX-0199 does not negatively impact the analgesic actions of morphine in freely-moving rats

[/vc_column_text][vc_separator type=”normal”][vc_single_image image=”211″ img_size=”full” qode_css_animation=””][vc_empty_space][/vc_column][/vc_row]